Trial Profile
Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 200 and 300 mg BIIB 722 CL Tablet Tid and 300 and 450 mg BIIB 722 CL Tablet Bid Over 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2014
Price :
$35
*
At a glance
- Drugs Sabiporide (Primary)
- Indications Ischaemic heart disorders
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Oct 2014 New trial record